The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis.

Autor:	Portaccio E; SOD Riabilitazione Neurologica, AOU Careggi, Florence, Italy.; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy., Bellinvia A; NEUROFARBA Department, University of Florence, Florence, Italy., Prestipino E; NEUROFARBA Department, University of Florence, Florence, Italy., Nacmias B; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.; NEUROFARBA Department, University of Florence, Florence, Italy., Bagnoli S; NEUROFARBA Department, University of Florence, Florence, Italy., Razzolini L; NEUROFARBA Department, University of Florence, Florence, Italy., Pastò L; SOD Riabilitazione Neurologica, AOU Careggi, Florence, Italy., Niccolai C; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy., Goretti B; NEUROFARBA Department, University of Florence, Florence, Italy., Fonderico M; NEUROFARBA Department, University of Florence, Florence, Italy., Zimatore GB; Ente Ecclestiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti, Italy., Losignore NA; Ente Ecclestiastico Ospedale Generale Regionale 'F. Miulli', Acquaviva delle Fonti, Italy., Sorbi S; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.; NEUROFARBA Department, University of Florence, Florence, Italy., Amato MP; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.; NEUROFARBA Department, University of Florence, Florence, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in neurology [Front Neurol] 2021 Mar 16; Vol. 12, pp. 645220. Date of Electronic Publication: 2021 Mar 16 (Print Publication: 2021).
DOI:	10.3389/fneur.2021.645220
Abstrakt:	Introduction: Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, involved in neuronal survival and synaptic plasticity. The BDNF Val66Met polymorphism is known to reduce BDNF expression and secretion; its role in multiple sclerosis (MS) is poorly investigated. Objectives and Methods: In this multicenter, retrospective study, we assessed the role of BDNF Val66Met polymorphism on cognitive and motor disability in MS patients consecutively referred to the University of Florence and the Hospital of Barletta. All patients underwent a genetic analysis for the presence of Val66Met polymorphism and a comprehensive neuropsychological examination on the Rao's Brief Repeatable Battery and the Stroop Color Word Test. Possible predictors of the Expanded Disability Status Scale (EDSS) score and number of failed neuropsychological tests were assessed through linear multivariable regression models. Results: Ninety-eight patients were recruited. Patients with the BDNF Val66Met polymorphism (35.7%) were more frequently males ( p = 0.020), more disabled ( p = 0.026) and, marginally, older ( p = 0.064). In the multivariable analysis, BDNF Val66Met polymorphism was associated with a better cognitive performance ( B = -1.1 ± 0.5, p = 0.027). Higher EDSS score was associated with a progressive disease course ( B = 3.4, p < 0.001) and, marginally, with the presence of the BDNF Val66Met polymorphism ( B = 0.56, p = 0.066). Discussion: Our results preliminarily suggest a protective role of BDNF Val66Met polymorphism against cognitive impairment in MS patients, possibly related to a detrimental effect of increased BDNF concentration in a neuroinflammatory environment. Competing Interests: EPr received compensation for travel grants, participation in advisory board, and/or speaking activities from Biogen, Merck Serono, Sanofi, Teva, and Novartis and serves on the editorial board of Frontiers in Neurology. LP received research support from Novartis, Biogen, and speaker honoraria from Teva. LR received research support from Novartis. GZ received travel funds and speaker honoraria from Sanofi-Genzyme, Novartis, Teva, Biogen, Almirall, Roche, and Merck. MA served on scientific advisory boards for and has received speaker honoraria and research support from Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis and serves on the editorial board of BMC Neurology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The Handling Editor declared a past co-authorship with some of the authors EPo, LR, and MA. (Copyright © 2021 Portaccio, Bellinvia, Prestipino, Nacmias, Bagnoli, Razzolini, Pastò, Niccolai, Goretti, Fonderico, Zimatore, Losignore, Sorbi and Amato.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu